Actively Recruiting
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Led by Beijing Tiantan Hospital · Updated on 2023-01-05
400
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.
CONDITIONS
Official Title
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children and adolescents aged 0 to 18 years diagnosed with medulloblastoma or other malignant central nervous system tumors such as glioma, ependymoma, germ cell tumors, tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma
- Eligible for and scheduled to receive surgical tumor resection
- Diagnosis confirmed by institutional neuro-pathological examination
- Consent given to join the study and comply with follow-up visits
- No prior radiotherapy or chemotherapy except corticosteroids
You will not qualify if you...
- Major perioperative complications causing significant and sudden health deterioration
- Major systemic illnesses like serious infection or significant organ dysfunction that may interfere with treatment or prognosis
- Major adverse events or sudden deterioration unrelated to the study
- Tumor tissue samples not suitable for genetic sequencing or laboratory tests
- Refusal to participate or withdrawal from the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hosiptal
Beijing, Beijing Municipality, China, 100050
Actively Recruiting
Research Team
T
Tao Jiang, MD
CONTACT
Y
Yahui Zhao, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here